Dell Inc. (NASDAQ: DELL) posted its highest-ever share of the global server market — 18.8% — as competitors International Business Machines Corp. (NYSE: IBM) and Hewlett-Packard Co. (NYSE: HPQ) both lost share. That s the good news for Dell; the bad news is that the worldwide market is shrinking.
According to the latest data from International Data Corp. (IDC), factory revenue in the worldwide server market fell 6.2% in the second quarter of 2013, from $12.64 billion in the second quarter of last year to $11.86 billion. IBM maintained its top spot in both market share and revenue, with a 27.9% share and sales of $3.31 billion. Those totals represent a loss of 1.2% of market share and 10% lower revenue.
HP remained in second place, but like IBM, saw market share decline from 29.5% in the second quarter of 2012 to 25.9% and revenues shrink by 17.5%, from $3.72 billion to $3.07 billion.
Dell�� market share rose from 16.0% to 18.8% and revenues rose 10.3%, from $2.02 billion to $2.23 billion.
Hot Railroad Stocks To Invest In Right Now: Zumiez Inc (ZUMZ)
Zumiez Inc. (Zumiez) is a specialty retailer of action sports related apparel, footwear, equipment and accessories operating under the Zumiez brand name. As of January 28, 2012, the Company operated 434 stores in the United States and 10 stores in Canada. In addition, the Company operates a Website that sells merchandise online. At January 28, 2012, its stores averaged approximately 2,900 square feet. Its apparel offerings include tops, bottoms, outerwear and accessories, such as caps, bags and backpacks, belts, jewelry and sunglasses. Zumiez�� footwear offerings primarily consist of action sports related athletic shoes and sandals. Its equipment offerings, or hardgoods, include skateboards, snowboards and ancillary gear, such as boots and bindings. The Company also offers a selection of other items, such as miscellaneous novelties.
The Company supplements its merchandise assortment with a select offering of private label products across many of its apparel product categories. During the fiscal year ended January 28, 2012 (fiscal 2011), its private label merchandise represented 17.7% of the Company�� net sales. The Company sources its private label merchandise from foreign manufacturers worldwide.
The Company competes with Abercrombie & Fitch, Aeropostale, American Apparel, American Eagle Outfitters, Billabong, CCS, Forever 21, Hollister, Hot Topic, Old Navy, Pacific Sunwear of California, The Buckle, Wet Seal, Tilly��, Urban Outfitters, Big 5 Sporting Goods, Dick�� Sporting Goods, Sport Chalet and The Sports Authority.
Advisors' Opinion:- [By Maria Armental and Tess Stynes var popups = dojo.query(".socialByline .popC"); ]
Zumiez Inc.(ZUMZ) said its fiscal first-quarter earnings were essentially flat with the year-ago period, though the teen apparel and sports-equipment retailer saw net sales increase.
- [By Sean Williams]
Zumiez (NASDAQ: ZUMZ )
Summer is all about being outside and taking up various sports and activities with friends and family. A little-known beneficiary could be action-sports apparel and accessories retailer Zumiez. It's pretty easy to be distrusting of the action-sports sector as a whole, because Pacific Sunwear�and Quiksilver's�inability to get the right product in its stores over the past couple of years doesn't inspire a lot of confidence in youth-oriented action-sports retailers. However, Zumiez has maintained strong pricing power through careful inventory management and has resisted the urge to expand into new locations beyond its ability to control that inventory. If consumers need surf, beach, or biking gear heading into summer, there's a possibility that Zumiez could be their destination.
Best Heal Care Companies To Watch For 2015: Intrexon Corp (XON)
Intrexon Corporation, incorporated on April 19, 2004, is engaged in the business of synthetic biology. Using the Company�� suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (DNA) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery.
The Company�� LEAP technology facilitates the automated identification of an individual cell with the highest levels of expression, quality and potency from a population of over 100,000 cells. Its mAbLogix platform complements UltraVector with a library of human antibodies that exceeds 500 million. By immortalizing human tonsils, which consists of lymphatic tissue containing B-cells, its mAbLogix platform creates a B-cell library that can generate antibodies against an almost infinite number of new antigens.
The UltraVector gene design and fabrication platform
The Company�� gene program design platform, which it refer to as UltraVector, is an integrated suite of tools comprising advanced DNA construction technology and components, cellular and protein engineering tools, computational models and statistical methods which facilitate the rapid design, build and testing of complex systems. The UltraVector platform allows the Company to translate gene programs into standard components that can be designed, manufactured and tested in an automated format. This technology enables it to engineer at the cellular level from biological sources.
UltraVector DNA design is computer-automated and ! utilizes a set of defined construction rules to assemble components that are stored in its DNA library. In addition to the number of gene components in its UltraVector library, it is designing and creating enzymatic and regulatory components that provide control over genome integration and gene regulation. Its RheoSwitch Therapeutic System is a three-component transcriptional regulator that provides inducible gene expression. The RheoSwitch Therapeutic System provides the ability to not only express proteins/enzymes of interest, but also the ability to control the level and timing of expression to achieve a biological outcome. Other ongoing programs include its Attsite recombinases, which mediate predictable gene exchange into host cells thereby eliminating many of the difficulties seen with traditional gene insertion.
Cell Systems Informatics
The Company�� Cell systems informatics permits design, as well as testing and learning about new gene targets or product pathways. Its bioinformatics software and database systems for mapping cellular pathways when combined with its genome-scale modeling and experimental data, including, gene expression profiling and protein engineering, enable the Company to optimize selection and development of gene programs and cellular systems for its collaborators. Its computational modeling and simulation platform enables the development of predictive computer models of organisms, from microbes to humans. This platform builds virtual cells from their basic molecular components, and can simulate the activity of the cell�� complete reaction network.
The Company is designing proteins with post-translational modifications. It is also working to develop enzyme inhibitors and fusion proteins for a variety of applications in human and animal therapeutics. Its protein engineering may utilize one or more of its technologies to obtain catalysis activitiesits component library, the generation of component variants sequence, evolutionary analy! sis and s! tructure-based sequence alignment, computer-aided drug discovery, de novo, or synthesized or generated, and comparative protein modeling, molecular dynamics simulation and free energy analysis, antibody design and humanization, antigenicity prediction, protein pharmacokinetics optimization, and/or in silico support of enzyme engineeringand quantitative structure-function relationships with machine learning algorithms to optimize, facilitate and prioritize protein variant libraries for the advancement of its collaborators.
LEAP-cell identification and selection
The Company�� Laser-Enabled Analysis and Processing technology (LEAP), is an instrument that merges semiconductor manufacturing technologies for cell processing applications to provide high levels of control and scale to cell purification and stem cell culture management. The LEAP platform can identify and purify cells of interest from large libraries of cells created by its UltraVector and bioinformatics technologies using a laser-based purification process, thereby providing a mechanism of testing the degree of protein expression in genetically modified cells, as well as means to learn from the genetic building process.
mAbLogix- antibody discovery
The Company�� mAbLogix antibody discovery platform, or mAbLogix platform, enables production of B-cell libraries for discovery of antibodies. The mAbLogix platform permits antigen targeting using fully human monoclonal and polyclonal antibodies. Its mAbLogix antibody discovery process consists of two major activities: the build of human B-cell libraries expressing a large number of antibodies, and the testing of these libraries based on an analysis of B-cells that express antibodies in response to a chosen antigen.
The Company competes with AbD SeroTec, Alexion Pharmaceuticals, Inc., XOMA Corporation, Genmab US, Inc., MorphoSys AG, NovImmune SA, Societe Des Systemes Biologiques, Adimab, LLC, ProMab Biotechnologies, Inc., Abpro, Inc.,! AIIM The! rapeutics and Open Monoclonal Technology, Inc.
Advisors' Opinion:- [By Ben Levisohn]
Overvalued companies include MWI Veterinary (MWIV) and�Stericycle (SRCL), while companies with attractive valuations include Cardinal Health (CAH), Selected Medical (SEM). He’s not a fan of Intrexon (XON) but calls�Aratana (PETX) a “hidden gem.”
- [By Jon C. Ogg]
Intrexon Corp. (NYSE: XON) was started as Buy at Mizuho Securities, started as Equal Weight at Barclays and started as Overweight at J.P. Morgan.
Nokia Corp. (NYSE: NOK) was raised to Hold from Sell at Deutsche Bank, raised to Neutral from Underperform at Credit Suisse and
Canaccord Genuity raised its price target to $5.50 from $3.30. - [By John Udovich]
Bubble talk, biotech IPO setbacks plus news�about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:
Best Heal Care Companies To Watch For 2015: Cooper Companies Inc (COO)
The Cooper Companies, Inc., incorporated on March 4, 1980, is a global medical device company. The Company operates through two business units, CooperVision, Inc. and CooperSurgical, Inc. CooperVision is a global manufacturer providing products for contact lens wearers. CooperSurgical focuses on supplying women's health clinicians with products and treatment options to improve the delivery of healthcare to women.
CooperVision develops, manufactures and markets a range of monthly, two-week and single-use contact lenses, featuring advanced materials and optics. CooperVision's products are designed to solve vision challenges such as astigmatism, presbyopia and ocular dryness with a collection of spherical, toric and multifocal contact lenses. CooperVision's products are primarily manufactured at its facilities located in Hampshire, United Kingdom, Juana Diaz, Puerto Rico, and Scottsville, New York. CooperVision distributes products from West Henrietta, New York, Fareham, United Kingdom, Liege, Belgium, and various smaller international distribution facilities. Under the Biofinity brand, CooperVision has launched monthly silicone hydrogel spherical, toric and multifocal lens products. CooperVision has also launched two-week silicone hydrogel spherical and toric lens products under its Avaira brand. During the fiscal year ended October 31, 2013 (fiscal 2013), the Company launched MyDay, its single-use spherical silicone hydrogel lens, in Europe. CooperVision's Proclear line of spherical, toric and multifocal lenses are manufactured with omafilcon, a material that incorporates Phosphorylcholine (PC) Technology that helps enhance tissue-device compatibility.
CooperSurgical offers an array of products used in the care and treatment of women's health. The Company participates in the women's healthcare market through offering quality products, technologies and service to clinicians worldwide. CooperSurgical collaborates with clinicians to identify products and new technologies from dis! posable products to instruments and equipment. The result is a portfolio of products that aid in the delivery of improved clinical outcomes that healthcare professionals use routinely in the diagnosis and treatment of a wide spectrum of women's health issues.
The Company competes with Johnson & Johnson Vision Care, Inc., CIBA Vision, Bausch & Lomb Incorporated, Boston Scientific, Johnson & Johnson's Ethicon Endo-Surgery and Ethicon Women's Health and Urology companies, Gyrus ACMI and Covidien.
Advisors' Opinion:- [By Monica Gerson]
The Cooper Companies (NYSE: COO) is expected to post its Q3 earnings at $1.90 per share on revenue of $443.65 million.
Infoblox (NYSE: BLOX) is projected to post its Q4 earnings at $0.01 per share on revenue of $60.49 million.
- [By Johanna Bennett]
Copper Cos (COO) shrank 6.5% to $125 after fiscal fourth-quarter earnings and the company�� full-year 2014 financial forecasts fell below expectations. For the period ended Oct. 31, Cooper earned $57.4 million, or $1.15 a share, down from $71.9 million, or $1.46 a share, in the prior-year period. Excluding impacts from a divestiture, adjusted earnings were $1.48, up from $1.47. Revenue gained 3.9% to $411.9 million. Excluding currency impacts, the growth was 7%. �For the new fiscal year, Cooper said it expects per-share earnings of $6.70 to $7 and revenue of $1.675 billion to $1.735 billion Analysts polled by Thomson Reuters were expecting $7 a share in profit and $1.71 billion in revenue.
- [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]
Cooper Cos.(COO) said its revenue jumped more than 6% in its fiscal first quarter, though its profit still fell as result of higher costs and expenses.
- [By Chuck Carnevale]
The following example looking at Cooper Cos. Inc. (COO), and reveals a very cyclical company that provides insight into the PE equals 15 hypotheses that this series of articles has presented. Clearly, price follows earnings even when earnings are dropping, and interestingly, the market tends to apply our standard PE equals 15 even when this happens.
Best Heal Care Companies To Watch For 2015: Dyax Corp.(DYAX)
Dyax Corp., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel biotherapeutics for unmet medical needs in the United States. The company utilizes its proprietary drug discovery technology, known as phage display, to identify antibody, small protein, and peptide compounds. It markets KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Dyax Corp. also provides KALBITOR Access program, which offers treatment support service for patients with HAE and their healthcare providers. In addition, the company is developing a pipeline of 17 product candidates, including 4 product candidates in Phase III clinical trial, 4 product candidates in Phase II clinical trial, and 9 product candidates in Phase 1 clinical trial for the treatment of atherosclerosis, multiple sclerosis, and oncology diseases. Further, it provides library licenses to use its phage display libr aries in connection with their internal therapeutic development programs; performs funded research for various collaborators; and offers patent licenses to other biopharmaceutical and pharmaceutical companies to use its phage display patents to discover and develop biologic compounds for use in specified fields. The company has strategic partnership agreement with Defiante Farmaceutica S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in Europe, North Africa, the Middle East, and Russia; an agreement with CMIC Co., Ltd to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other angioedema indications in Japan; and an license and collaboration agreement with Cubist Pharmaceuticals, Inc. to develop and commercialize the formulation of ecallantide for the reduction of blood loss during surgery in North America and Europe. Dyax Corp. was founded in 1989 and is headquartered in Cambri dge, Massachusetts.
Advisors' Opinion:- [By Brian Orelli]
Dyax (NASDAQ: DYAX ) and its investors will also be keeping a close eye on trebananib's development. The biotech helped Amgen discover trebananib and is due milestone payments for successful development of the drug.
- [By Jake L'Ecuyer]
Dyax (NASDAQ: DYAX) shares tumbled 10.39 percent to $9.10 after the company priced 8 million shares at $9.25 per share.
Raptor Pharmaceuticals (NASDAQ: RPTP) was down, falling 10.04 percent to $13.31 after the company reported Q4 results. Raptor Pharmaceutical posted a Q4 loss of $0.20 per share, versus the projected loss of $0.16 per share.
- [By Laura Brodbeck]
Friday
Earnings Expected From: Epizyme (NASDAQ: EPZM), Dyax Corp (NASDAQ: DYAX) Economic Releases Expected: ��German GDP, German business climate index, Italian retail sales.Get all the #premarket info by listening in to Benzinga's morning show at 8:00 am EST Monday-Friday!
Best Heal Care Companies To Watch For 2015: 3D Systems Corp. (DDD)
3D Systems Corporation, through its subsidiaries, engages in the design, development, manufacture, marketing, and servicing of 3D printers and related products, print materials, and services. The company�s principle print engines comprise stereolithography, selective laser sintering, multi-jet modeling, film transfer imaging, selective laser melting, and plastic jet printers. Its 3D printers convert data input from computer-aided design software or 3D scanning and sculpting devices to produce physical objects from engineered plastic, metal, and composite print materials. The company also blends, markets, sells, and distributes various consumables, engineered plastics, metal materials, and composites; and offers various software tools, as well as pre-sale and post-sale services, including applications development, installation, warranty, and maintenance. In addition, it provides custom parts services, such as precision plastic and metal parts service and assembly capabilit ies. The company markets its stereolithography materials under the Accura and RenShape; laser sintering materials under the DuraForm, CastForm, and LaserForm; and materials for professional printers under the VisiJet brands. It primarily serves manufacturers of automotive, aerospace, computer, electronic, defense, education, consumer, energy and healthcare products, as well as original equipment manufacturers, government agencies, universities, and independent service bureaus. The company sells its products and services through its direct sales organization, sales agents, resellers, and distributors primarily in the United States, Europe, and the Asia-Pacific region. 3D Systems Corporation was founded in 1986 and is headquartered in Rock Hill, South Carolina.
Advisors' Opinion:- [By Chris Preston]
ExOne shares are up 132% since the company went public in early February. And fellow 3-D printer 3D Systems (DDD) is up a whopping 479% since the company debuted in May 2011. Perhaps that's where ExOne is headed in the next year or two.
Best Heal Care Companies To Watch For 2015: Array BioPharma Inc.(ARRY)
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases in North America, Europe, and the Asia Pacific. Its programs under development include ARRY-520, a kinesin spindle protein inhibitor in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie-2 dual inhibitor in Phase 1 clinical trial for patients with myelodysplastic syndrome; ARRY-380, a HER2 inhibitor in Phase 1 clinical trial for breast cancer; ARRY-797, a p38 inhibitor in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist in Phase 1 clinical trial for allergic inflammation. The company?s partnered drugs in clinical development comprise Selumetinib and AZD8330 MEK inhibitors for cancer in Phase 2 trial; MEK162 and MEK300 MEK inhibitors for cancer in Phase 2 trial; Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 trial; ARRY-543, a HER2/EGFR inhibitor in Phase 2 trial for solid tumors; and LY2603618, a ChK-1 inhibitor in Phase 2 trial for cancer. Its partnered drugs in clinical development also include AMG 151, a glucokinase activator in Phase 1b trial for Type 2 diabetes; GDC-0068, a AKT inhibitor in Phase 1b trial for cancer; VTX-2337, a toll-like receptor in Phase 1b trial for cancer; VTX-1463, a toll-like receptor in Phase 1b trial for allergy; ARRY-382, a cFMS inhibitor in Phase 1 trial for cancer; and ARRY-575 and GDC-0425, which are ChK-1 inhibitors in Phase 1 trial for cancer. The company has collaborations with Amgen, Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Genentech, Inc.; Novartis International Pharmaceutical Ltd.; InterMune, Inc.; Eli Lilly and Company; and VentiRx Pharmaceuticals, Inc for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
Advisors' Opinion:- [By Sean Williams]
What: Shares of Array BioPharma (NASDAQ: ARRY ) , a biopharmaceutical company focused on the development of small molecule drugs for the treatment of cancer and inflammatory diseases, soared as much as 29% after the company reported positive phase 2 data on ARRY-502, an experimental drug designed to treat mild to moderate persistent allergic asthma.
- [By Sean Williams]
Array BioPharma (NASDAQ: ARRY ) presented some particularly intriguing findings with its MEK inhibitor, selumetinib, which it has licensed out to AstraZeneca�to treat uveal melanoma (cancer of the eye). Historically this is a very difficult to treat disease, but initial studies of selumetinib more than doubled the time it took for the disease to progress compared to the current standard of treatment, temozolomide. In trials, selumetinib delivered 15.9 weeks without disease progression, an overall response rate of 50%, and major tumor shrinkage exhibited in 15% of patients. For temozolomide, steady disease was only established for a median of seven weeks with no tumor shrinkage present.�
- [By Sean Williams]
Shareholders "nudged" Array BioPharma (NASDAQ: ARRY ) higher by nearly 18% on the week after it announced positive mid-stage data on ARRY-502, a treatment for mild to moderate persistent allergic asthma. In its mid-stage trial, ARRY-502 met its primary endpoint of improving lung function as measured by forced expiratory volume in one second, or FEV1. In the overall trial, FEV1 increased by 3.9% compared to the placebo, while a specified subset of patients in the Th2 Biomarker group saw their FEV1 jump by 6.8% relative to the placebo. ARRY-502 also met a number of secondary endpoints. Since the asthma market is a crowded field, Array also put the feelers out there that it's looking for a licensing partner to help take this experimental drug into the next stage.
- [By John Udovich]
Biotech and the cancer treatment segment of the biotech market has been a hot area for some time with important cancer stocks like large cap Celgene Corporation (NASDAQ: CELG) and small caps�Array BioPharma (NASDAQ: ARRY), Cancer Genetics Inc (NASDAQ: CGIX), EXACT Sciences Corporation (NASDAQ: EXAS) and�MetaStat Inc (OTCMKTS: MTST) all producing a steady flow of important news�for investors this week or in recent weeks. Consider the following:
Best Heal Care Companies To Watch For 2015: Kraft Foods Group Inc (KRFT)
Kraft Foods Group, Inc. (Kraft Foods Group), incorporated on March 16, 2012, operates food and beverage businesses in North America. The Company manufactures and markets food and beverage products, including convenient meals, refreshment beverages and coffee, cheese and other grocery products, in the United States and Canada, under a stable of iconic brands. Its product categories span breakfast, lunch and dinner meal occasions, both at home and in foodservice locations. The Company sells its products to supermarket chains, wholesalers, supercenters, club stores, mass merchandisers, distributors, convenience stores, drug stores, gasoline stations, value stores and other retail food outlets in the United States and Canada. On September 14, 2012, the Company�� parent company, Kraft Foods Inc. (Kraft ParentCo), issued a press release relating to the anticipated trading markets for Kraft Foods Inc. and Kraft Foods Group, Inc. common stock through the completion of its spin-off from Kraft Foods Inc. In October 2012, Mondelez International, Inc. completed the spin-off of North American grocery business, Kraft Foods Group. In June 2013, Kraft Foods Group Inc announced plans to create two new, standalone business units: Meals and Desserts, and Enhancers and Snack Nuts.
The Company�� brand portfolio consists of food brands in North America, including three brands: Kraft cheeses, dinners and dressings; Oscar Mayer meats, and Maxwell House coffees- plus over 20 brands. It manufactures and sells food and beverage products in 50 categories. The Company operates in five segments: U.S. Beverages, which manufactures packaged juice drinks, powdered beverages and coffee; U.S. Cheese, which manufactures processed, natural and cream cheeses; U.S. Convenient Meals, which manufactures processed meats and lunch combinations; U.S. Grocery, which manufactures spoonable and pourable dressings, condiments, desserts, packaged dinners and snack nuts, and Canada & N.A. Foodservice, which sells products that span ! all of its segments and includes the Canadian and Puerto Rico grocery business, the North American foodservice operations and the North American Grocery Export Business.
U.S. Beverages
During the year ended December 31, 2011, the Company�� U.S. Beverages segment contributed 16% of its combined net revenues. This segment manufactures refreshment beverages, including Capri Sun (under license) and Kool-Aid packaged juice drinks, Kool-Aid, Crystal Light and Country Timepowdered beverages and MiO liquid concentrate, and coffee products, including Maxwell House, Gevalia and Yuban coffees, Maxwell House Internationalbeverage mixers and Tassimo (under license) hot beverage system.
U.S. Cheese
During 2011, U.S. Cheese segment had contributed 20% of the Company�� combined net revenues. This segment manufactures processed cheese, including Velveeta and Cheez Whiz processed cheeses, Kraft and Deli Deluxe processed cheese slices, Kraft grated cheeses and Polly-O and Athenos hummus and cheeses; natural cheese, including Kraft and Cracker Barrel natural cheeses, and cream cheese, including Philadelphia cream cheese and cooking creme.
U.S. Convenient Meals
During 2011, the Company�� U.S. Convenient Meals segment contributed 18% of its combined net revenues. This segment�� principal brands and products include Oscar Mayer lunch meats, hot dogs and bacon, Lunchables lunch combinations, Boca soy-based meat alternatives, and Claussen pickles.
U.S. Grocery
During 2011, the Company�� U.S. Grocery segment contributed 25% of its combined net revenues. This segment�� principal brands and products include Kraft and Kraft Deluxe macaroni & cheese dinners, Planters nuts, trail mixes and peanut butter, Corn Nuts corn snacks, Jell-O dry packaged desserts and refrigerated gelatin and pudding snacks, Cool Whip whipped topping, Jet-Puffed marshmallows, Baker�� chocolate and baking ingredients, Kraft and Miracle Whip sp! oonable d! ressings, Kraft and Good Seasons salad dressings, A.1. steak sauce, Kraft and Bull��-Eye barbecue sauces, Grey Poupon mustards, Shake N��Bake coatings, Stove Top stuffing mix, Taco Bell Home Originals (under license) meal kits, Velveeta shells and cheese dinners, and Velveeta Skillets meal kits.
Canada & N.A. Foodservice
During 2011, the Company�� Canada & N.A. Foodservice segment contributed 21% of its combined net revenues. The principal products and brands in this segment span all of its segments. Canadian grocery offerings include Nabob coffee and Kraft peanut butter, as well as a range of products in the Grocery Business Lines. The North American foodservice business sells branded products, including Maxwell House coffee, A.1. steak sauce and a range of Kraft sauces, dressings and cheeses, and serves the needs of restaurants and other foodservice operations. Puerto Rico grocery offerings include all grocery business lines, except for powdered and liquid concentrate beverages, such as Crystal Light, Tang and MiO. The North American Grocery Export Business products and brands span all grocery business lines, except for powdered and liquid concentrate beverages and certain products sold under brands, such as Philadelphia cream cheese and Kraftmayonnaise, which marketed and sold locally by Kraft ParentCo in countries outside the United States and Canada.
Advisors' Opinion:- [By Demitrios Kalogeropoulos]
Food and snacks
At a glance, Kraft Foods (NASDAQ: KRFT ) looks like a spanking new company. Its stock just started trading in 2012, after all. But Kraft Foods' stellar portfolio -- including billion-dollar brands like Kraft and Oscar Mayer -- has taken decades to build. Fresh from its spin-off from Mondelez International, Kraft is a pure play on snacks and food in the North American market that has a lot of room to expand there. After a 10% run in the stock so far this year, Kraft is still cheaper than global competitor PepsiCo. And the company's 4% yield makes it one of the highest yielding stocks around. - [By Tom Taulli]
Valuation. Kellogg stock is far from cheap. The current price-to-earnings ratio is at 24X, which is well above some of its peers.�General Mills�(GIS), for example, has a multiple of 18X and�Kraft Foods�(KRFT) is trading at 17X.
No comments:
Post a Comment